This trial is evaluating whether Elranatamab will improve 4 primary outcomes and 69 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy..
This trial requires 589 total participants across 4 different treatment groups
This trial involves 4 different treatments. Elranatamab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Patients treated with elranatamab had better QOL, including improvements in pain control, fatigue, and MIPQ, compared with placebo. Elranatamab had no effect on immunoglobulin levels." - Anonymous Online Contributor
"There have been many important advances made in our understanding of MM biology and treatment over the past decade. However, despite these methodological advancements, patient survival remains suboptimal and optimal therapy still needs to be determined." - Anonymous Online Contributor
"Elranatamab is commonly used alone or in combination with other drugs; however, no clinical trial has investigated its use in combination with bortezomib in the treatment of multiple myeloma. The phase III ONO-AFFIRM trial found significant improvement in PFS and OS when elranatamab was added to bortezomib plus dexamethasone." - Anonymous Online Contributor
"The most common adverse events were headache (14%), fatigue (11%), nausea (10%), dizziness (9%), dry mouth (8%), constipation (6%), injection site reactions (3%) and rash (2%). There was no incidence of hypertriglyceridaemia, hepatitis, pneumonitis or hypersensitivity reaction." - Anonymous Online Contributor
"The majority of people with MM receive some type of chemotherapy. More than two thirds of people have this treatment before they reach their 2 year endpoint. Most will receive either [thalidomide (Thalomid)] or lenalidomide (Revlimid), both of which have been shown to improve overall survival. There is no clear evidence that one agent is better than another for people in early stages of MM. People with advanced MM may benefit from [thalidomide] and those with higher risk of refractoriness from previous chemotherapy may benefit from lenalidomide. There is little evidence whether different regimens work differently in people with MM." - Anonymous Online Contributor
"Elranatamab was well tolerated as an adjuvant therapy in patients with high risk MM who had received two prior lines of therapy. Median PFS and OS were de facto not reached due to early termination of the study. The most common adverse events were fatigue, headache, nausea, vomiting, diarrhoea, rash, and infusion related reactions. There were no serious adverse events associated with elranatamab. Elranatamab is a novel immunomodulatory agent that shows promise for improving prognosis in high risk MM patients treated with bortezomib, lenalidomide, dexamethasone, and cyclophosphamide." - Anonymous Online Contributor
"Elranatamab was generally well tolerated In a recent study, but there were a few transient grade 3/4 adverse events associated with infusion. These include nausea, vomiting, headache, dizziness, fatigue, and paraesthesia (pins and needles), which occurred most often during the first infusion. Longer terms safety data are awaited." - Anonymous Online Contributor
"The present data provide no evidence for an increased prevalence of MM in family members. We cannot exclude a possible association between MM and other hereditary disorders; however, our data do not support a hereditary etiology for MM." - Anonymous Online Contributor
"A self-reported history of bone pain during a physical exam was found to be the best indicator of MM diagnosis. Other physical findings were suggestive of MM, but lacked specificity. The presence of bone lesions and/or anemia were not specific for MM. Only the presence of an elevated serum paraprotein (a protein in the blood) confirmed the diagnosis of MM." - Anonymous Online Contributor
"In a recent study, the overall survival was not indicative of the survival rates for either myeloma or AL amyloidosis; however, myeloma had a better outcome than AL amyloidosis." - Anonymous Online Contributor
"[The chances of developing MM are low unless you have an inherited genetic predisposition to develop the disease.] In contrast, the probability of developing other hematological cancers increases substantially [(figure 1)] if you are Caucasian. [Body figure] Ethnicity does not appear to be a risk factor for the development of non-Hodgkin’s lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia, or polycythemia vera." - Anonymous Online Contributor